Equity
€3,709 from €66,012 in 2017
Equity fell by 94% in 8 years.
PHARMAGIVES
Lifetime
12 annual accounts with figures on one time axispeak €221,286 (2014)
€147,548▲ 2.2%
lowest -€41,622 (2020)
-€276▲ €22
peak €66,012 (2017)
€3,709▼ 6.9%
€339,816▲ 12.5%
peak 2.3 FTE (2016)
-not published
Board2 names since 2020
1 directorFONTAINE Viviane
Documentsfilings and deeds
22-07-20269 days before the deadline
2025micro format
Loss of €276
Key points
from the 2025 annual accountsLosses
-€574 in two years
The 2024 and 2025 financial years closed with a loss. 2024 was the heaviest.
Turnover
≈ €450,000 estimated
The accounts state no turnover.
Debts
€339,816 99% of the balance sheet
Financial debts 29%Suppliers 41%Taxes and wages 6%Other 24%
Of this, €254,413 falls due within a year.
Staff
5 employees on 31-12-2025
In 2025, 5 people joined and 2 left.
Filings
12 annual accounts since 2014
Three of the last ten came late. The 2020 accounts came latest: 27 days after the end of the period.
Checked score
80
Excellent
Financially stronger than 28% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.4% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.9%
01-2025: 0.9%● unchanged vs 12-2024
02-2025: 0.8%▼ -0.1 percentage points vs 01-2025
03-2025: 0.8%● unchanged vs 02-2025
04-2025: 0.9%▲ +0.1 percentage points vs 03-2025
05-2025: 0.8%▼ -0.1 percentage points vs 04-2025
06-2025: 0.8%● unchanged vs 05-2025
07-2025: 1.0%▲ +0.2 percentage points vs 06-2025
08-2025: 1.5%▲ +0.5 percentage points vs 07-2025highest value
09-2025: 0.5%▼ -1.0 percentage point vs 08-2025
10-2025: 0.5%● unchanged vs 09-2025
11-2025: 0.5%● unchanged vs 10-2025
12-2025: 0.5%● unchanged vs 11-2025
01-2026: 0.5%● unchanged vs 12-2025
02-2026: 0.5%● unchanged vs 01-2026
03-2026: 0.5%● unchanged vs 02-2026
04-2026: 0.5%● unchanged vs 03-2026
05-2026: 0.5%● unchanged vs 04-2026
06-2026: 0.5%● unchanged vs 05-2026
07-2026: 0.5%● unchanged vs 06-2026
08-2026: 0.4%▼ -0.1 percentage points vs 07-2026lowest value
09-2026: 0.4%● unchanged vs 08-2026lowest value
10-2026: 0.4%● unchanged vs 09-2026lowest value
11-2026: 0.4%● unchanged vs 10-2026lowest value
Financial strengthWeak
Score breakdown
raises risk
Sector: Retail trade (NACE 47)
Equity €3,709 (1.1% of total assets)
lowers risk
Size: total assets €343,524
Founded in 2013
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 20% of them on solvency, 17% on liquidity, 45% on profitability and 29% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 1,037 companies had the same profile as PHARMAGIVES has now. Each dot stands for 3 companies, two years later.
93.7%
were still trading
2.9%
stopped another way
2.9%
went bankrupt
Another 0.5% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of PHARMAGIVES itself is lower: 0.4% within 12 months. It rests on far more data about PHARMAGIVES than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,037 companies, not a prediction for PHARMAGIVES. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 23% of 22924 sector peers (2025).
NBB · sector comparisonPosition among 22924 sector peers
Solvency
better than 23%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-07-2026, 9 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
9 days early
2024
6 days late
2023
28 days early
2022
28 days early
2021
18 days late
2020
27 days late
2019
18 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 5 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 22 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0526969524
Resignation: FONTAINE Viviane (director)
Appointment: FONTAINE Viviane (director) · “La gestion d’une entreprise pharmaceutique par un ou plusieurs praticiens habilités à exercer la profession de…” (deed in French) · Director discharge: FONTAINE Viviane · General meeting of 15-11-2023 · Gazette deed
New manager
Fontaine Viviane appointed, L'hermitte Martine resigned · General meeting of 31-12-2019 · Gazette deed
Incorporation
published on 24-04-2013 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMAGIVES Huy | €343,524 | €147,548 | 1.1% | - |
| Apotheek Veldstraat Ghent | €365,048 | €148,636 | 36.8% | 1.3 |
| PHARMACIE VANHEES Forest | €346,872 | €139,200 | 49.3% | 1.3 |
| Pharmacie Marie-Anne TYCHON Liège | €362,681 | €131,572 | 78.6% | - |
| APOTHEEK HANDZAME Kortemark | €344,380 | €168,726 | 15.1% | - |
| Pharmacie MORY Sint-Gillis (bij-Brussel) | €349,639 | €131,549 | 28.9% | - |
| PHARMACIE GODIN Auderghem | €314,922 | €146,490 | 23.1% | 0.8 |
These companies have the same main activity as PHARMAGIVES: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €315,000 and €365,000, founded between 2010 and 2014.
Official details
Source: KBO- Status
- Active since 22-04-2013Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 2 others
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.218.493.3344500 Huy, since 22-04-2013
- Financial year end
- 31 December
- Peppol
- Reachable since 11-12-2025
Annual accounts 2025
- €343,524▲ 12.2%
- Employeeson 31-12-2025
- 5▲ 150%
- Filing
- Filed on 22-07-2026, 9 days before the end of the filing period
Insights on PHARMAGIVES
PHARMAGIVES files the micro format. That format states no turnover. The gross margin fell from €221,286 in 2014 to €147,548 in 2025.
The balance sheet grew most in 2020 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMAGIVES
- What is the company number of PHARMAGIVES?
- The company number of PHARMAGIVES is 0526.969.524. The VAT number is the same number with BE in front: BE 0526.969.524.
- Where is PHARMAGIVES based?
- The registered office is at Chaussée d'Andenne 60, 4500 Huy.Company details
- What does PHARMAGIVES do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMAGIVES?
- PHARMAGIVES is a private limited company (BV).
- When was PHARMAGIVES founded?
- PHARMAGIVES was founded on 22-04-2013.
- Is PHARMAGIVES still active?
- Yes, PHARMAGIVES is an active enterprise in the KBO register.
- How many employees does PHARMAGIVES have?
- PHARMAGIVES had an average of 2.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does PHARMAGIVES fall under?
- In its 2025 annual accounts, PHARMAGIVES states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of PHARMAGIVES?
- The turnover in financial year 2025 is ≈ €450,000. This figure is estimated from the gross margin of €147,548 and 31 comparable companies (NACE 477). It probably lies between €310,000 and €840,000.
- Is PHARMAGIVES profitable?
- In financial year 2025, PHARMAGIVES made a loss of €276.
- Where can I find the annual accounts of PHARMAGIVES?
- PHARMAGIVES filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMAGIVES due?
- PHARMAGIVES must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.